<DOC>
	<DOCNO>NCT02683785</DOCNO>
	<brief_summary>This randomize , Phase IIa , multicentre , double-blind , placebo-controlled parallel group study primary objective ass efficacy potential GSK3196165 pain , subject active inflammatory hand osteoarthritis ( HOA ) . Approximately 40 subject enrol study , follow screen period 4 week . The total treatment period 12 week , follow period complete Week 22 . At least 40 subject randomize across two treatment arm , either placebo GSK3196165 1:1 ratio .</brief_summary>
	<brief_title>A Study Investigate Efficacy Safety GSK3196165 Inflammatory Hand Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Age &gt; =18 year time signing informed consent . Meets American College Rheumatology ( ACR ) classification osteoarthritis ( OA ) respond analgesic ( level 1 2 ) nonsteroidal antiinflammatory drug ( NSAIDs ) least 10 day past 3 month . Active disease screen randomization least two swollen tender proximal interphalangeal ( PIP ) and/or distal interphalangeal ( DIP ) joint affected hand . Signs inflammation synovitis MRI scan affect hand . Must subject 's self assessment 24hour average hand pain intensity baseline least ' 5 ' 11point Numerical Rating Scale ( NRS , 010 ) . Weight &gt; =45 kilogram ( kg ) . Male female subject eligible participate long meet agree abide contraceptive criterion . Diffusing capacity lung carbon monoxide ( DLCO ) &gt; =70 % predict ; force expiratory volume 1 second ( FEV1 ) &gt; =80 % predict . No evidence active latent infection Mycobacterium tuberculosis ( TB ) . Pregnant lactating woman . History clinically significant inflammatory disease inflammatory HOA , especially , limited , rheumatoid arthritis spondylarthropathies . Diagnosis rheumatoid arthritis , fibromyalgia , gout , calcium pyrophosphate deposition disease ( CPPD ) , pseudogout , hemochromatosis inflammatory rheumatological autoimmune disorder . Clinical suspicion , previous investigation CPPD pseudogout , history chondrocalcinosis . Any injury , medical surgical procedure affect joint ( ) may interfere evaluation target HOA joint ( ) . History infect joint prosthesis time , prosthesis still situ . History leg ulcer , catheter , chronic sinusitis recurrent chest urinary tract infection . Any surgical procedure , include bone joint surgery/synovectomy within 12 week prior Day 1 plan surgery within duration study followup period . History respiratory disease ( opinion investigator ) would compromise subject safety ability subject complete study ( e.g . significant interstitial lung disease , pulmonary fibrosis , chronic obstructive pulmonary disease ( COPD ) , moderatesevere asthma , bronchiectasis , previous pulmonary alveolar proteinosis [ PAP ] ) . Clinicallysignificant unstable ( opinion investigator ) persistent cough dyspnea unexplained . Significant unstable uncontrolled acute chronic disease , opinion investigator , could confound result study put subject undue risk . A history malignancy . Hereditary acquire immunodeficiency disorder , include immunoglobulin deficiency . Current/previous Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) 1 2 infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Pain intensity</keyword>
	<keyword>Hand Osteoarthritis</keyword>
	<keyword>GSK3196165</keyword>
	<keyword>AUSCAN</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Numerical Rating Scale</keyword>
</DOC>